På gymnasiet kan du ikke bare sygemelde dig og slippe bekymringerne. Hvis dit fravær bliver for højt, risikerer du at blive ...

Det har længe set sort ud for Novo Nordisk-aktien, men torsdag blev et nyt lavpunkt nået. Ved selskabets generalforsamling faldt aktien til 480 kroner – et niveau, der ikke er set siden februar 2023.

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

Nedturen fortsætter for Novo Nordisk-aktien, der har kurs mod laveste niveau i to år. Og især én problematik optager Danmarks største profesionelle Novo-investor, kapitalforvalteren C WorldWide. »Jeg ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...

The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has been approved for early trials in China and the U.S.

No­vo Nordisk is re­or­ga­niz­ing its re­search and ear­ly de­vel­op­ment unit in an ef­fort to “fu­ture-proof the or­ga­ni­za­tion” and “sig­nif­i­cant­ly in­crease ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff.

If you suffered a loss in Novo Nordisk you have until March 25, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve ...

HYDERABAD (Reuters) -Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most ...

This move positions Lilly ahead of rival Novo Nordisk, whose widely popular drug Ozempic belongs to the same category, as both companies compete in the rapidly growing Indian market. Eli Lilly says it ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...